Emcure Pharmaceuticals Overview
- Year Founded
-
1981
- Status
-
Public
- Employees
-
10,852
- Stock Symbol
-
544210
- Investments
-
7
- Share Price
-
$12.51
- (As of Tuesday Closing)
Emcure Pharmaceuticals General Information
Description
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics.
Contact Information
Website
www.emcure.comCorporate Office
- Plot Number P-1 and P-2, IT-BT Park, Phase II
- M.I.D.C.,Hinjawadi
- Pune, 411057
- India
Corporate Office
- Plot Number P-1 and P-2, IT-BT Park, Phase II
- M.I.D.C.,Hinjawadi
- Pune, 411057
- India
Emcure Pharmaceuticals Stock Performance
As of 22-Apr-2025, Emcure Pharmaceuticals’s stock price is $12.51. Its current market cap is $2.37B with 189M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.51 | $12.64 | $10.41 - $18.83 | $2.37B | 189M | 29.4K | $0.39 |
Emcure Pharmaceuticals Financials Summary
As of 31-Dec-2024, Emcure Pharmaceuticals has a trailing 12-month revenue of $893M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
|---|---|---|---|---|
| EV | 3,315,695 | |||
| Revenue | 893,304 | 795,062 | 738,634 | 773,909 |
| EBITDA | 170,730 | 150,708 | 147,838 | 183,694 |
| Net Income | 72,606 | 60,177 | 66,256 | 88,877 |
| Total Assets | 936,064 | 812,722 | 799,631 | |
| Total Debt | 0 | 279,994 | 284,321 | 292,398 |
Emcure Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Emcure Pharmaceuticals Comparisons
Industry
Financing
Details
Emcure Pharmaceuticals Competitors (96)
One of Emcure Pharmaceuticals’s 96 competitors is Evofem Biosciences, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evofem Biosciences | Formerly VC-backed | San Diego, CA | ||||
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| Acerus Pharmaceuticals | Corporation | Mississauga, Canada | ||||
| United Therapeutics | Formerly VC-backed | Silver Spring, MD | ||||
| Novartis | Corporation | Basel, Switzerland |
Emcure Pharmaceuticals Patents
Emcure Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2864541-T3 | Improved kit for the preparation of carmustine injectable solutions | Active | 04-Oct-2018 | ||
| EP-3632411-A1 | Improved kit for preparing injectable carmustine solutions | Active | 04-Oct-2018 | ||
| EP-3632411-B1 | Improved kit for preparing injectable carmustine solutions | Active | 04-Oct-2018 | ||
| CA-3057479-A1 | Improved kit for preparing injectable carmustine solutions | Active | 04-Oct-2018 | ||
| CA-3057479-C | Improved kit for preparing injectable carmustine solutions | Active | 04-Oct-2018 | A61K9/0019 |
Emcure Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Emcure Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Emcure Pharmaceuticals Investments & Acquisitions (7)
Emcure Pharmaceuticals’s most recent deal was a Secondary Transaction - Private with Sunsure Solarpark Twelve for . The deal was made on 25-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sunsure Solarpark Twelve | 25-Jul-2024 | Secondary Transaction - Private | Energy Production | ||
| Bharadwaj Pharma | 01-Jan-2016 | Buyout/LBO | Pharmaceuticals | ||
| International Pharmaceutical Generics | 09-Nov-2015 | Buyout/LBO | Drug Discovery | ||
| Ranbaxy (Six Brands) | 24-Mar-2015 | Buyout/LBO | Pharmaceuticals | ||
| Sun Pharma (Tamlet) | 24-Mar-2015 | Buyout/LBO | Pharmaceuticals |
Emcure Pharmaceuticals Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Bharadwaj Pharma | Hamburg, Germany | 2009 | |
| Tillomed Laboratories | Luton, United Kingdom | 1990 |
Emcure Pharmaceuticals FAQs
-
When was Emcure Pharmaceuticals founded?
Emcure Pharmaceuticals was founded in 1981.
-
Where is Emcure Pharmaceuticals headquartered?
Emcure Pharmaceuticals is headquartered in Pune, India.
-
What is the size of Emcure Pharmaceuticals?
Emcure Pharmaceuticals has 10,852 total employees.
-
What industry is Emcure Pharmaceuticals in?
Emcure Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Emcure Pharmaceuticals a private or public company?
Emcure Pharmaceuticals is a Public company.
-
What is Emcure Pharmaceuticals’s stock symbol?
The ticker symbol for Emcure Pharmaceuticals is 544210.
-
What is the current stock price of Emcure Pharmaceuticals?
As of 22-Apr-2025 the stock price of Emcure Pharmaceuticals is $12.51.
-
What is the current market cap of Emcure Pharmaceuticals?
The current market capitalization of Emcure Pharmaceuticals is $2.37B.
-
What is Emcure Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Emcure Pharmaceuticals is $893M.
-
Who are Emcure Pharmaceuticals’s competitors?
Evofem Biosciences, Glenmark Pharmaceuticals, Acerus Pharmaceuticals, United Therapeutics, and Novartis are some of the 96 competitors of Emcure Pharmaceuticals.
-
What is Emcure Pharmaceuticals’s annual earnings per share (EPS)?
Emcure Pharmaceuticals’s EPS for 12 months was $0.39.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
